Your browser doesn't support javascript.
loading
Effectiveness of Regdanvimab Treatment in High-Risk COVID-19 Patients to Prevent Progression to Severe Disease.
Lee, Ji Yeon; Lee, Jee Young; Ko, Jae-Hoon; Hyun, Miri; Kim, Hyun Ah; Cho, Seongcheol; Lee, Yong Dae; Song, Junghoon; Shin, Seunghwan; Peck, Kyong Ran.
  • Lee JY; Division of Infectious Diseases, Department of Internal Medicine, Keimyung University Dongsan Hospital, Keimyung University School of Medicine, Daegu, South Korea.
  • Lee JY; Department of Internal Medicine, Seoul Red Cross Hospital, Seoul, South Korea.
  • Ko JH; Division of Infectious Diseases, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
  • Hyun M; Division of Infectious Diseases, Department of Internal Medicine, Keimyung University Dongsan Hospital, Keimyung University School of Medicine, Daegu, South Korea.
  • Kim HA; Division of Infectious Diseases, Department of Internal Medicine, Keimyung University Dongsan Hospital, Keimyung University School of Medicine, Daegu, South Korea.
  • Cho S; Department of Internal Medicine, Seoul Red Cross Hospital, Seoul, South Korea.
  • Lee YD; Department of Internal Medicine, Seoul Red Cross Hospital, Seoul, South Korea.
  • Song J; Department of Internal Medicine, Seoul Red Cross Hospital, Seoul, South Korea.
  • Shin S; Department of Internal Medicine, Seoul Red Cross Hospital, Seoul, South Korea.
  • Peck KR; Division of Infectious Diseases, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Front Immunol ; 12: 772320, 2021.
Article en En | MEDLINE | ID: mdl-34899724
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Inmunoglobulina G / Anticuerpos Neutralizantes / Anticuerpos Monoclonales Humanizados / SARS-CoV-2 / Tratamiento Farmacológico de COVID-19 Tipo de estudio: Etiology_studies / Observational_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Año: 2021 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Inmunoglobulina G / Anticuerpos Neutralizantes / Anticuerpos Monoclonales Humanizados / SARS-CoV-2 / Tratamiento Farmacológico de COVID-19 Tipo de estudio: Etiology_studies / Observational_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Año: 2021 Tipo del documento: Article